No abstract available.
Cytokines ; Monocytes*

Infantile acute hemorrhagic edema of the skin(IAHE) is a benign disease which affects infants between 4 months and 2 years of age and is characterized by palpable ecchymotic purpura and edema on the limb and face. We report a typical case of IAHE, which was presenting a cockade, annular, reticulated, and iris-like purpura and edema on the face and extremities in a 19-month-old male infant. We consider it to be a new disease category because its characteristics different markedly from HenochSchoenlein purpura in several clinical and histopathologic findings.
Edema* ; Extremities ; Humans ; Infant ; Male ; Purpura ; Skin*

PURPOSE: This study was aimed to determine the relationship between osteopontin(OPN) and osteoclast, especially focused on whether ostecolast could produce osteopontin or not. MATERIALS AND METHODS: Osteoclasts were isolated from the giant cell tumor of proximal tibia and seeded on the 13 mm round cover slip resided in 24 multi-well plates for culture. After 2 days, osteclasts on the cover slip were fixed with cold acetone for 3 minutes and immunocytochemistry was done with rabbit osteopontin antibody. For in situ RT-PCR, osteoclasts on the cover-slips were fixed with 4% paraformaldehyde for 4 hours and were treated to pepsin. PR-PCR was done and the PCR producst were stained with anti-digoxigenin-AP. RESULTS: Osteopontins were found on the surface of the osteoclast by immunocytochemistry, and intense osteopontin mRNAs were found by in situ RT-PCR. CONCLUSION: We have identified that osteoclast could synthesize the osteopontin, and confirmed that in situ RT-PCR was a very useful method in expressing small amount of mRNA in case of mixed cell culture. Further study was needed to identify the action of the osteopontin produced by the osteoclast.
Acetone ; Cell Culture Techniques ; Giant Cell Tumors ; Immunohistochemistry ; Osteoclasts* ; Osteopontin* ; Pepsin A ; Polymerase Chain Reaction ; RNA, Messenger ; Tibia

Limb salvage operations for osteosarcoma of the extremity usually consist of wide excision and skeletal reconstruction. Most osteosarcoma patients are anemic prior to the surgery as majority of them undergo preoperative neo-adjuvant chemotherapy; thus, it is necessary to treat anemia before and after the surgery since limb salvage operation tends to accompany significant blood loss. Despite the fact that blood transfusion has bad influence on prognosis, complication, and postoperative outcome of cancer patients, it is still considered as a standard management to fix anemia for limb salvage operations. We would like to present a case report in which the authors succeeded in performing limb salvage operations on patients with distal femur osteosarcoma without transfusion.
Anemia ; Blood Transfusion* ; Drug Therapy ; Extremities ; Femur* ; Humans ; Limb Salvage* ; Osteosarcoma* ; Prognosis

No abstract available.
Humans* ; Interleukin-10*

No abstract available.
Surgery, Oral* ; Transplants* ; Veins*

BACKGROUND: There are many evidences that inflammation is an important determinant of the development of atherosclerosis and one of the systemic markers of inflammation, C-reactive protein(CRP), is associated with extent of coronary artery disease and risk of coronary events. We assessed the time response of CRP response after coronary angioplasty and it's influence on the clinical restenosis in angina patients. MATERIALS AND METHODS: Patients included 36 angina patients undergoing single vessel angioplasty. Levels of CRP were measured before and 12, 24, 48, and 72 hours after angioplasty. Clinical restenosis was assessed at 6 months after procedure. RESULTS: Baseline CRP level was 0.30+/-0.01 mg/dL in stable and 0.46+/-0.28 mg/dL in unstable angina patients(p<0.05). After angioplasty, CRP level was increased with peak at 24 hour and persisted to 72 hours after angioplasty. At 24 hour after angioplasty, the magnitude of CRP change was 0.32+/-0.31 mg/dL in stable and 0.79+/-0.73 mg/dL in unstable angina patient(p<0.05). The change of CRP level was not associated with troponin-T after angioplasty. In unstable angina patients, clinical restenosis was developed in 8% of patients with low baseline CRP levels and in 50% of those with high baseline CRP levels more than 0.6 mg/dL(p<0.05). CONCLUSION: In unstable angina patients, inflammatory response is more increased than stable angina patients, and increased inflammatory response effects on the restenosis after coronary angioplasty.
Angina, Stable ; Angina, Unstable ; Angioplasty* ; Atherosclerosis ; C-Reactive Protein* ; Coronary Artery Disease ; Humans ; Inflammation ; Troponin T

PURPOSE: We evaluated the relative long-term longitudinal changes in the levels of serial prostate specific antigen in healthy men without urinary tract infection and initial PSA of 4.0ng/ml or less. MATERIALS AND METHODS: Between February 1996 and June 2000, the rate of PSA change (PSAV) in 1,132 healthy men with an initial PSA of 4.0ng/ml or less who were clinically free of urinary tract infection and known prostate disease were analyzed. In all cases, a minimum of 2 PSA levels were measured at intervals of at least 12month. The influence of age, initial PSA and interval between measurements were assessed. RESULTS: The mean age, initial PSA, interval between measurements, change in PSA and PSAV were 45.2 (24-80) years, 1.05 (0.04-4.0)ng/ml, 19.2 (12-39) month, 0.13 ( 1.0-3.1)ng/ml and 0.08 ( 0.8-1.22)ng/ml/year. A cumulative frequency plot of PSAV demonstrated that 50%, 95% and 97% of subjects had PSAV 0.06ng/ml/year, 0.55 ng/ml/year and 0.60ng/ml/year or less, respectively. PSAV was correlated with age (r=0.090, p=0.002) and initial PSA (r=0.331, p <0.001) but not with interval between measurements (r=0.046, p=0.132). Age was directly correlated with initial PSA (r=0.118, p<0.05). However, age was not correlated with PSAV (r=0.052, p>0.05) when adjusted by the initial PSA level. Percentage of the men with PSAV of great than 0.75ng/ml/year was 1.8% (20/1,132); 0.6% (4/708) for those whose initial PSA were less than 1.0ng/ml, 1.7% (6/358) for 1.1-2.0ng/ml and 15.1% (10/66) for 2.1-4.0ng/ml. CONCLUSIONS: Among men with normal PSA whose PSA is sampled over relatively long-term interval, PSAV is directly correlated with initial PSA but not with age and interval between measurements. Men with a PSA of 2.0ng/ml or less are at low risk for abnormal PSAV and annual PSA monitoring may not be necessary, but the annual longitudinal monitoring may be clinically useful in men with an initial PSA of 2.1-4.0ng/ml. Large prospective studies are required to assess the precise cut-off point of PSAV for Korean men in the early detection of prostate cancer.
Humans ; Male ; Prostate* ; Prostate-Specific Antigen* ; Prostatic Neoplasms ; Urinary Tract Infections

BACKGROUND: It is well known that ischemic preconditioning protects the heart against infarction or arrhythmias from a subsequent ischemic injury. Two phases of the effect of preconditioning has been explored, early protection and second window of protection at 24 hours. The late protection was seen in some animal model, but the precise mechanism is controversal. This study was designed to evaluate the late cardioprotective effect and role of HSP70 in ischemic preconditioning of cat heart. METHODS: Two groups of cats were studied. Control animals were subjected to an episode of 40-min coronary artery occlusion followed by 30-min reperfusion. Experimental animals were subjected to ischemic preconditioning before the 40-min ishcemia/reperfusion. The preconditioning protocol was comprised of three 5-min episodes of ischemia interspersed by 10-min episodes of reperfusion. After sustained ischemia and reperfusion, left ventricular risk area and infart area were measured by injection of Evans blue bye and triphenyltetrazolium staining, and myocardial HSP70 mRNA was examined in risk(left ventricular anterior wall) and nonrisk(left ventricular posterior wall) area using northern blot hybridization. HSP70 mRNA expression was quantified as a percent of GAPDH. The late cardioprotective effects of ischemic preconditioning were determined by infarct size (% area at risk). RESULTS: Infarct size was markedly limited by ischemic preconditioning when compared with the control group (18.5+/-6.9% vs 38.5+/-11.1%; p<0.001). HSP70 mRNA expression in risk area was much higher in preconditioning group than control group(78+/-12% vs 41+/-11%; p<0.01). But, there was no significant difference of HSP70 mRNA expression in the posterior wall between control and ischemic preconditioning group. CONCLUSIONS: These data suggest that ischemic preconditioning have delayed myocardial protective effect from ischemia. The increase in myocardial HSP70 mRNA may be one of the contributing factors to the delayed cardioprotective effects of ischemic preconditioning in cats.
Animals ; Arrhythmias, Cardiac ; Blotting, Northern ; Cats* ; Coronary Vessels ; Evans Blue ; Heart* ; Heat-Shock Proteins* ; Hot Temperature* ; HSP70 Heat-Shock Proteins ; Infarction ; Ischemia ; Ischemic Preconditioning* ; Models, Animal ; Reperfusion ; RNA, Messenger

PURPOSE: Antiphospholipid syndrome is a disorder of recurrent vascular thrombosis, recurrent abortion, thrombocytopenia, neurologic disorders associated with the elevation of antiphospholipid antibodies. The aim of our study was to characterize the patient profile and frequency of antiphospholipid syndrome in patients with deep vein thrombosis of the lower legs. METHOD: From January 1998 to December 1999, 25 patients with the lower leg swelling were classified according to their risk factors. Deep vein thrombosis was confirmed by radiologic diagnosis such as duplex ultrasonography or venography. The items for the identification of hypercoagulability were antithrombin III, protein-C, protein-S, lupus anticoagulant, anticardiolipin antibody (IgG). For the differential diagnosis of systemic lupus erythematosus, we tested antinuclear antibody and anti-dsDNA for the patients with positive results of antiphospholipid antibodies. Antiphospholipid syndrome was diagnosed according to its criteria. RESULT: Of the 25 patients with the lower leg swelling, 17 patents (68%) were revealed to have deep vein thrombosis. In that 17 patients, 8 patients showed hypercoagulabilities including 4 patients (24%) with positive test for lupus anticoagulant, 1 patient (6%) with combined multiple abnormalities of protein C and protein S deficiencies and lupus anticoagulant positivity, 2 patients (12%) with antithrombin III deficiencies, 1 patient (6%) with protein C deficiency, and there was no patient with IgG type anticardiolipin antibody positivity. According to the American Rheumatism Association criteria (ARA), there was no patient with systemic lupus erythematosus, but we could find out 1 patient (6%) who met the dagnostic criteria of antiphospholipid syndrome. CONCLLUSION: In our study, 6% (1of 17) of patient with the lower leg deep vein thrombosis revealed antiphospholipid syndrome. We described the clinical profile and diagnostic process of antiphospholipid syndrome in this study.
Abnormalities, Multiple ; Abortion, Habitual ; Antibodies, Anticardiolipin ; Antibodies, Antinuclear ; Antibodies, Antiphospholipid ; Antiphospholipid Syndrome* ; Antithrombin III ; Antithrombin III Deficiency ; Diagnosis ; Diagnosis, Differential ; Female ; Humans ; Immunoglobulin G ; Leg ; Lupus Coagulation Inhibitor ; Lupus Erythematosus, Systemic ; Nervous System Diseases ; Phlebography ; Pregnancy ; Protein C ; Protein C Deficiency ; Protein S Deficiency ; Rheumatic Diseases ; Risk Factors ; Thrombocytopenia ; Thrombophilia ; Thrombosis ; Ultrasonography ; Venous Thrombosis*